Tokyo, Japan

Hiroko Yoshida

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2004-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Hiroko Yoshida: Innovator in Therapeutic Antibodies

Introduction

Hiroko Yoshida is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 4 patents to her name, her work focuses on innovative solutions for treating cancer and autoimmune diseases.

Latest Patents

One of her latest patents involves anti-DR5 antibodies, polynucleotides, and methods. This invention relates to an antibody that exhibits a therapeutic effect on cancer, autoimmune diseases, or inflammatory diseases. The antibody demonstrates cytotoxic activity against cells expressing death domain-containing receptors through apoptosis. The objective of this invention is to provide a pharmaceutical with a therapeutic effect on cancer. Notably, this novel anti-DR5 antibody is capable of inducing apoptosis in cells and has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Career Highlights

Hiroko Yoshida has worked with notable companies such as Sankyo Company, Limited and Daiichi Sankyo Company, Limited. Her experience in these organizations has contributed to her expertise in the field of therapeutic innovations.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues, including Nobufusa Serizawa and Kimihisa Ichikawa. These partnerships have further enhanced her research and development efforts.

Conclusion

Hiroko Yoshida's contributions to the field of therapeutic antibodies highlight her innovative spirit and dedication to improving healthcare solutions. Her work continues to pave the way for advancements in cancer treatment and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…